Atai Life Sciences (Nasdaq:ATAI) recently announced positive results from a Phase 1 study testing KUR-101 for opioid use disorder. KUR-101 is an oral formulation of the kratom alkaloid mitragynine. Atai subsidiary Kures is leading the effort to test the potential of mitragynine, which acts as a partial mu-opioid receptor agonist. Kratom itself is a source of controversy.…
Atai Life Sciences shares positive results from Phase 1 study of opioid use disorder
Berlin-headquartered Atai Life Sciences (Nasdaq:ATAI) is sharing positive initial results from a Phase 1 clinical study of KUR-101, an oral formulation of deuterated mitragynine, in patients with opioid use disorder. Mitragynine is a primary active alkaloid of the kratom plant (Mitragyna speciosa). Atai’s KUR-101 is an oral formulation of deuterated mitragynine. Atai subsidiary Kures is leading the…
Could vaccines ease the opioid overdose crisis?
Vaccines are playing a central role in the fight against COVID-19. They also may hold promise to help relieve the opioid overdose crisis that has worsened along with the pandemic. That’s the argument that two psychiatrists make in a recent JAMA article, “The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 Pandemic.” Antifentanyl vaccines…